TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18211278
Drug: Assessment/attention comparison
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment/attention comparison group with typical treatment available
Study: 12949850
Drug: Risperidone 1
Normalized name: risperidone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 1 to 3 mg/day
Study: 10966692
Drug: Oral temazepam
Normalized name: Temazepam
DrugBank: Temazepam acetate (DB14671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral temazepam (group B)
Study: 10966692
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam (group C)
Study: 10966692
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam and fentanyl (group D)
Study: 8990802
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g of calcium/day for 4 weeks
Study: 30914044
Drug: Delayed antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed antibiotic prescription (DAP) for respiratory tract infections (RTIs)
Study: 22782352
Drug: Pioglitazone 30
Normalized name: pioglitazone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30 mg daily for 14 days
Study: 20107799
Drug: Suramin plus
Normalized name: suramin
DrugBank: Suramin (DB04786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suramin plus docetaxel 75 mg/m²
Study: 20107799
Drug: Suramin plus
Normalized name: suramin
DrugBank: Suramin (DB04786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suramin plus docetaxel 56 mg/m²
Study: 20107799
Drug: Suramin plus
Normalized name: suramin
DrugBank: Suramin (DB04786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suramin plus gemcitabine 1,250 mg/m²
Study: 18485031
Drug: Suspension technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension technique
Study: 18485031
Drug: No suspension
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No suspension technique
Study: 12122554
Drug: SSM+ (semisolid
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSM+ (semisolid meal with 2.5 g GG)
Study: 7494721
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group program aimed at diminishing affective components of negative attitudes towards neuroleptics
Study: 2089252
Drug: Low-dose calcitriol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose calcitriol (0.25 microgram b.i.d.) and 1 g of supplemental calcium therapy
Study: 2089252
Drug: Ergocalciferol (50,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ergocalciferol (50,000 units twice a week) and 1 g of supplemental calcium
Study: 19321575
Drug: 5 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g/d seaweed (Alaria)
Study: 16481636
Drug: Calcium plus
Normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium plus vitamin D supplementation (500 mg of elemental calcium as calcium carbonate with 200 IU of vitamin D3 twice daily for an average of 7.0 years)
Study: 11382835
Drug: Vascupump treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vascupump treatment (20 sessions of 45 minutes each)
Study: 11382835
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with Vascupump and Pentoxillin (3 fl/per diem for 20 days)
Study: 8058074
Drug: Digoxin (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (0.25 mg daily)
Study: 26375689
Drug: GLP-1 receptor
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 receptor agonist liraglutide
Study: 24660607
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (10 sessions of puncturing acupuncture at various acupoints including Hegu (LI 4))
Study: 16442211
Drug: Tamsulosin OCAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin OCAS 0.4 mg
Study: 16442211
Drug: Alfuzosin XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin XL 10 mg
Study: 14709244
Drug: Ribavirin (RBV)
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin (RBV) 400 mg bid plus interferon alpha‐2b (IFN‐alpha) 5 mU daily for the first 6 weeks, followed by 3 mU tiw until completing 6 months of therapy (induction arm)
Study: 14709244
Drug: Ribavirin (RBV)
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin (RBV) 400 mg bid plus interferon alpha‐2b (IFN‐alpha) 3 mU tiw (control arm)
Study: 11112016
Drug: High-dose ATG
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ATG (9 mg/kg body weight, single intravenous injection)
Study: 11112016
Drug: High-dose ATG
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ATG
Study: 9420308
Drug: RT inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT inhibitors (Nevirapine and Zidovudine)
Study: 2872811
Drug: Terazosin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin (1 to 40 mg, single daily doses)
Study: 29387931
Drug: Single instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single instillation of THP (30 mg/50 mL) immediately after TURBT (Group A)
Study: 25308780
Drug: i-gel size
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: i-gel size 1
Study: 23965882
Drug: MMF1 (mycophenolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF1 (mycophenolate mofetil after 2 weeks of conventional treatment)
Study: 23965882
Drug: MMF2 (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF2 (combination therapy with non-steroidal anti-inflammatory drugs, prednisone, and MMF)
Study: 16868226
Drug: Goserelin (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin (3.6 mg subcutaneously every 4 weeks for 12 weeks)
Study: 12182257
Drug: Cefditoren 200
Normalized name: cefditoren 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefditoren 200 mg BID for 10 days
Study: 12182257
Drug: Cefditoren 400
Normalized name: cefditoren 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefditoren 400 mg BID for 10 days
Study: 12182257
Drug: Cefuroxime 250
Normalized name: cefuroxime 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 250 mg BID for 10 days
Study: 12182257
Drug: Cefadroxil 500
Normalized name: cefadroxil 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxil 500 mg BID for 10 days
Study: 12182257
Drug: Cefditoren 200
Normalized name: cefditoren 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefditoren 200 mg vs Cefuroxime
Study: 12182257
Drug: Cefditoren 200
Normalized name: cefditoren 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefditoren 200 mg vs Cefadroxil
Study: 12182257
Drug: Cefditoren 400
Normalized name: cefditoren 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefditoren 400 mg vs Cefadroxil
Study: 12182257
Drug: Cefditoren 400
Normalized name: cefditoren 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefditoren 400 mg
Study: 10482825
Drug: Fluconazole 100
Normalized name: fluconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 100 mg daily for 5 months
Study: 10482825
Drug: Fluconazole (continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (continued treatment in phase 2)
Study: 8738765
Drug: Once-daily aminoglycoside
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily aminoglycoside dosing (ODA)
Study: 25057140
Drug: Live Educational
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live Educational Music Therapy
Study: 25057140
Drug: Recorded Educational
Normalized name: Recorlev
DrugBank: Levoketoconazole (DB05667)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recorded Educational Music Therapy
Study: 25057140
Drug: Recreational Music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recreational Music Therapy
Study: 25057140
Drug: Recreational Music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recreational Music Therapy without Education
Study: 17219174
Drug: Intensified training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified training (IT) followed by a 7-day taper
Study: 17219174
Drug: Normal training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal training (NT) followed by a 7-day taper
Study: 20486868
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) for 6 months
Study: 9590915
Drug: Intraligamentary technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraligamentary technique of anesthetic administration (ILA)
Study: 8250678
Drug: Morning light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning light therapy (2500 lux for 1 hour for 1 week)
Study: 8250678
Drug: Evening light
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening light therapy (2500 lux for 1 hour for 1 week)
Study: 2951811
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 40 micrograms ipratropium bromide and 100 micrograms fenoterol (Duovent)
Study: 29370572
Drug: Gevokizumab (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gevokizumab (60 mg every 4 weeks subcutaneously)
Study: 27881152
Drug: In-bed cycling
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-bed cycling sessions (same number, frequency and treatment time as the intervention group)
Study: 17987065
Drug: Dopamine D2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine D2 receptor (D2-R) density in TS patients with OCD
Study: 17987065
Drug: Dopamine release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine release (DA(rel)) and serotonin 5-HT2A receptor binding potential (5-HT2A BP) in TS+OCD subjects
Study: 15717937
Drug: Non-stent therapies
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-stent therapies
Study: 12876113
Drug: Brief explanation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief explanation to parents regarding the self-limited nature of AOM and the controversy regarding antibiotic prescription.
Study: 2063503
Drug: Adaptogens treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptogens treatment (0.15 U/kg im insulin, 0.1 mg/kg prednisolone, 0.2 mg/kg dibazol, 250 mg/kg methyluracil daily for 1 week preoperatively)
Study: 2063503
Drug: Prednisolone (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (0.2 mg/kg intravenous administration)
Study: 15736113
Drug: Methionine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine (0.1 g/kg)
Study: 15736113
Drug: Homocysteine (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homocysteine (0.01 g/kg)
Study: 15736113
Drug: N-Acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-Acetylcysteine (NAC) (0.1 g/kg)
Study: 12952516
Drug: Physiotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy treatment without deep breathing exercises
Study: 12952516
Drug: Physiotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy treatment with deep breathing exercises (control)
Study: 2004365
Drug: Hexamethylene bisacetamide
Normalized name: 1,6-hexamethylene diisocyanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexamethylene bisacetamide administered nasogastrically at 12 g/m2/day
Study: 2004365
Drug: Hexamethylene bisacetamide
Normalized name: 1,6-hexamethylene diisocyanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexamethylene bisacetamide administered nasogastrically at 24 g/m2/day
Study: 2004365
Drug: Hexamethylene bisacetamide
Normalized name: 1,6-hexamethylene diisocyanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexamethylene bisacetamide administered nasogastrically at 30 g/m2/day
Study: 2004365
Drug: Hexamethylene bisacetamide
Normalized name: 1,6-hexamethylene diisocyanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexamethylene bisacetamide administered nasogastrically
Study: 2004365
Drug: Hexamethylene bisacetamide
Normalized name: 1,6-hexamethylene diisocyanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexamethylene bisacetamide administered nasogastrically or parenterally
Study: 6838743
Drug: Sitting position
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitting position after extradural injection
Study: 25483468
Drug: Vaccine efficacy
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine efficacy
Study: 17242321
Drug: Daily SSRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily SSRI use
Study: 15655141
Drug: Ciclopirox shampoo
Normalized name: ciclopirox Shampoo Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclopirox shampoo twice weekly
Study: 15655141
Drug: Ciclopirox shampoo
Normalized name: ciclopirox Shampoo Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclopirox shampoo once weekly
Study: 15655141
Drug: Prophylactic ciclopirox
Normalized name: Ciclopirox
DrugBank: Ciclopirox (DB01188)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic ciclopirox once weekly
Study: 15655141
Drug: Ciclopirox shampoo
Normalized name: ciclopirox Shampoo Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclopirox shampoo (both treatment and prophylaxis)
Study: 9527938
Drug: EMLA analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMLA analgesic cream
Study: 9527938
Drug: sucrose and
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sucrose and EMLA combination
Study: 2231096
Drug: Conventional steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional steroid therapy, 1000 mg/day for 3 days (group 1)
Study: 2231096
Drug: Conventional steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional steroid therapy, 500 mg/day for 3 days (group 2)
Study: 2231096
Drug: Conventional steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional steroid therapy, 250 mg/day for 3 days (group 3)
Study: 28185976
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral glibenclamide daily for 10 days, n = 29
Study: 28185976
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in the same dosage, n = 23
Study: 22998386
Drug: Essential oil
Normalized name: Essential oil
DrugBank: Rosemary oil (DB14689)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential oil mouth rinse (Listerine(®) Coolmint; Johnson & Johnson) used twice per day as an adjunct to mechanical plaque control.
Study: 22998386
Drug: Placebo mouth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo mouth rinse used twice per day as an adjunct to mechanical plaque control.
Study: 17266173
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin E supplementation (1200 mg/day)
Study: 11174476
Drug: All dosage
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All dosage groups of 17beta-estradiol (Menorest)
Study: 7653756
Drug: Somatostatin bolus
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin bolus 3.5 micrograms.kg‐1 intravenously plus an infusion of somatostatin 3.5 micrograms.kg‐1.h‐1
Study: 2671362
Drug: 2% butoconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% butoconazole vaginal cream for three days
Study: 2671362
Drug: 2% miconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% miconazole vaginal cream for seven days
Study: 21906647
Drug: MF59®-adjuvanted quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59®-adjuvanted quadrivalent influenza vaccine (QIV)
Study: 21906647
Drug: Trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent inactivated influenza vaccines (TIV)
Study: 19193652
Drug: Lo-Pro GlideScope
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lo-Pro GlideScope (LP-G)
Study: 1961649
Drug: Intensified conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified conventional treatment (n = 44)
Study: 1961649
Drug: Regular treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular treatment (n = 52)
Study: 6119495
Drug: 1% glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% glyceryl trinitrate ointment
Study: 28651207
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (MCT and CBT)
Study: 20814331
Drug: Risperidone 1-mg
Normalized name: risperidone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 1-mg single oral dose
Study: 18061060
Drug: Test vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test vaccine (inactivated candidate vaccine for JEV)
Study: 18061060
Drug: Licensed vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licensed vaccine (mouse‐brain‐derived vaccine)
Study: 18061060
Drug: Test vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test vaccine
Study: 18061060
Drug: Licensed vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licensed vaccine
Study: 16283239
Drug: Pioglitazone (15‐45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (15‐45 mg/day)
Study: 16283239
Drug: Gliclazide (80‐320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide (80‐320 mg/day)
Study: 16283239
Drug: Metformin (850‐2,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850‐2,550 mg/day)
Study: 12297475
Drug: Low-dose mitomycin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose mitomycin C (MMC) 2-4 mg, 4-6 mg, or 6-8 mg depending on tumor size
Study: 12297475
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy regimen: 10 mg MMC, 40 mg PI, 300 mg CBP
Study: 10416522
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone for 14 days
Study: 2917676
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied betamethasone-17-valerate (0.1% solution and cream) applied twice daily for 7 days
Study: 2917676
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied betamethasone-17-valerate (0.1% solution and cream) applied twice daily for 14 days
Study: 31432510
Drug: Balloon catheter
Normalized name: Paclitaxel coated angioplasty balloon catheter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balloon catheter (50-mL for 12 hours)
Study: 31432510
Drug: Oxytocin (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (low-dose infusion)
Study: 30599916
Drug: Achillea millefolium
Normalized name: ACHILLEA MILLEFOLIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Achillea millefolium 250 mg/day
Study: 30599916
Drug: Achillea millefolium
Normalized name: ACHILLEA MILLEFOLIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Achillea millefolium 500 mg/day
Study: 29231586
Drug: Acupuncture (2-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (2-3 times per week, total of 14 treatments)
Study: 21546491
Drug: 25% human
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% human albumin (ALB) administered intravenously at 2 g/kg within 5 hours of stroke onset
Study: 21546491
Drug: 25% human
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% human albumin (ALB) administered intravenously at 2 g/kg within 5 hours of stroke onset (among thrombolyzed subjects)
Study: 16048138
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (10 g orally twice per day for 6 days, then 5 g daily)
Study: 12351464
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) spray for 4 weeks
Study: 12351464
Drug: Placebo spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo spray for 4 weeks
Study: 8010550
Drug: Parenteral magnesium
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral magnesium sulfate (MgSO4)
Study: 8010550
Drug: Combined MgSO4-digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined MgSO4-digoxin therapy
Study: 2470988
Drug: Cibenzoline 130
Normalized name: cibenzoline
DrugBank: Cibenzoline (DB13358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cibenzoline 130 mg every 12 h
Study: 2470988
Drug: Cibenzoline 160
Normalized name: cibenzoline
DrugBank: Cibenzoline (DB13358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cibenzoline 160 mg every 12 h
Study: 2470988
Drug: Quinidine 300
Normalized name: hydroquinidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine 300 mg every 6 h
Study: 2470988
Drug: Quinidine 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine 400 mg every 6 h
Study: 11763992
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and furosemide administered in the morning (05:00)
Study: 11763992
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and furosemide administered in the evening (17:00)
Study: 15226138
Drug: Revised National
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Revised National Institute on Drug Abuse standard intervention